Format

Send to

Choose Destination
Nat Chem Biol. 2014 Apr;10(4):305-12. doi: 10.1038/nchembio.1471. Epub 2014 Mar 2.

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.

Author information

1
1] KINOMEscan Division of DiscoveRx Corporation, San Diego, California, USA. [2].
2
1] Nuffield Department of Clinical Medicine, University of Oxford, Structural Genomics Consortium, Oxford, UK. [2] Nuffield Department of Clinical Medicine, University of Oxford, Target Discovery Institute (TDI), Oxford, UK. [3].
3
1] BioSeek Division of DiscoveRx Corporation, San Francisco, California, USA. [2].
4
Nuffield Department of Clinical Medicine, University of Oxford, Target Discovery Institute (TDI), Oxford, UK.
5
1] Nuffield Department of Clinical Medicine, University of Oxford, Structural Genomics Consortium, Oxford, UK. [2] Nuffield Department of Clinical Medicine, University of Oxford, Ludwig Institute for Cancer Research (LICR), Oxford, UK.
6
KINOMEscan Division of DiscoveRx Corporation, San Diego, California, USA.
7
Division of Hematology/Oncology, University of California-San Francisco, San Francisco, California, USA.
8
1] Nuffield Department of Clinical Medicine, University of Oxford, Structural Genomics Consortium, Oxford, UK. [2] Nuffield Department of Clinical Medicine, University of Oxford, Target Discovery Institute (TDI), Oxford, UK.

Erratum in

  • Nat Chem Biol. 2014 Aug;10(8):692.

Abstract

Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clinical responses to targeted therapies. The difficulty of discovering kinase inhibitors with an appropriate multitarget profile has, however, necessitated the application of combination therapies, which can pose major clinical development challenges. Epigenetic reader domains of the bromodomain family have recently emerged as new targets for cancer therapy. Here we report that several clinical kinase inhibitors also inhibit bromodomains with therapeutically relevant potencies and are best classified as dual kinase-bromodomain inhibitors. Nanomolar activity on BRD4 by BI-2536 and TG-101348, which are clinical PLK1 and JAK2-FLT3 kinase inhibitors, respectively, is particularly noteworthy as these combinations of activities on independent oncogenic pathways exemplify a new strategy for rational single-agent polypharmacological targeting. Furthermore, structure-activity relationships and co-crystal structures identify design features that enable a general platform for the rational design of dual kinase-bromodomain inhibitors.

Comment in

PMID:
24584101
PMCID:
PMC3998711
DOI:
10.1038/nchembio.1471
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center